Oncorus to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 09, 2022 07:00 ET
|
Oncorus, Inc.
Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed...
Oncorus Announces Promotion of John Goldberg, M.D. to Chief Medical Officer
February 22, 2022 08:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus to Present at the H.C. Wainwright BioConnect Virtual Conference
January 03, 2022 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus to Present at Upcoming Investor Conferences
November 23, 2021 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus to Present at the Jefferies London Healthcare Conference
November 17, 2021 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports Initial Safety, Tolerability, Immune Activation and Positive Clinical Response Data from its Ongoing Phase 1 Clinical Study of ONCR-177, its Lead Viral Immunotherapy Candidate, at SITC 2021
November 12, 2021 07:00 ET
|
Oncorus, Inc.
ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid...
Oncorus Announces Exclusive Licensing Agreement with Gaeta Therapeutics Ltd. for Use of Locally Delivered Interleukin-12 (IL-12) via Oncolytic Viral Expression in Combination with Immune Checkpoint Inhibitors
November 11, 2021 07:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Announces Details of Upcoming ONCR-177 Phase 1 Initial Clinical Data Presentation at the Society for Immunotherapy of Cancer’s (SITC) 2021 Annual Meeting
November 09, 2021 08:00 ET
|
Oncorus, Inc.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today...
Oncorus Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 03, 2021 07:00 ET
|
Oncorus, Inc.
To report initial data from ongoing Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate, ONCR-177, in multiple solid tumor indications at the upcoming...